Medy Tox Ownership

086900 Stock  KRW 133,200  400.00  0.30%   
The market capitalization of Medy Tox is W1 Trillion. Medy Tox holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.
Some institutional investors establish a significant position in stocks such as Medy Tox in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Medy Tox, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Medy Tox. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Medy Stock Ownership Analysis

About 27.0% of the company shares are owned by insiders or employees . The company recorded earning per share (EPS) of 1813.31. Medy Tox had not issued any dividends in recent years. The entity had 21:20 split on the 28th of December 2022. Medy-Tox Inc., a biopharmaceutical company, develops, manufactures, markets, and sells botulinum toxin and hyaluronic acid dermal filler products primarily in South Korea. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea. MedyTox is traded on Korean Securities Dealers Automated Quotations in South Korea. For more info on Medy Tox please contact HyunHo Jung at 82 4 3217 1555 or go to https://www.medy-tox.co.kr.

Medy Tox Outstanding Bonds

Medy Tox issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Medy Tox uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Medy bonds can be classified according to their maturity, which is the date when Medy Tox has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Pair Trading with Medy Tox

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medy Tox position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medy Tox will appreciate offsetting losses from the drop in the long position's value.

Moving together with Medy Stock

  0.72005935 Samsung ElectronicsPairCorr
  0.75005930 Samsung ElectronicsPairCorr
  0.8005490 POSCO HoldingsPairCorr

Moving against Medy Stock

  0.8035420 NaverPairCorr
The ability to find closely correlated positions to Medy Tox could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medy Tox when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medy Tox - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medy Tox to buy it.
The correlation of Medy Tox is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medy Tox moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medy Tox moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medy Tox can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Medy Stock

Medy Tox financial ratios help investors to determine whether Medy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medy with respect to the benefits of owning Medy Tox security.